Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Oxford University, through its innovation arm Oxford University Innovation (OUI), has entered into an option agreement for a universal influenza vaccine with US-based startup Blue Water Vaccines (BWV), which is raising $15m to support development of the flu shot.

3D rendering of microscopic virus in front of abstract background © Shutterstock

Developed by scientists at the University’s Department of Zoology the vaccine protects against all influenza strains by targeting parts of the virus that induce a protective immune response but are also limited in variability. The technology has the potential of providing life-long immunity against flu.

Influenza is a major respiratory pathogen. It is estimated that there are over almost 500,000 deaths a year caused by influenza, with somewhere between three to five million severe cases of illness annually. The virus is estimated to cost $87.1bn in absenteeism in the US alone. Current influenza vaccines target highly variable epitopes of the virus which evolve and change annually, meaning flu vaccines need to be updated and redistributed every season while only typically providing protection to 50% of the individuals who receive it. Conversely, the universal flu vaccine developed at Oxford University targets epitopes that are both naturally immunogenic and limited in variability, allowing for a vaccine that protects against all influenza strains and avoids the need to be regularly updated.

Read more (University of Oxford website)

Similar stories

Asthma drug budesonide shortens recovery time in non-hospitalised patients with COVID-19

Clinical Trials Coronavirus COVID-19 Research

Inhaled budesonide, a common corticosteroid, is the first widely available, inexpensive drug found to shorten recovery times in COVID-19 patients aged over 50 who are treated at home and in other community settings, reports the PRINCIPLE trial in 1,779 participants.

AIMday in Women's Health - registration for academics now open

Events Innovation

Are you an academic interested in finding out how your knowledge can be used to solve industry challenges? Would you like to widen your network? Meet potential collaborators / future employees? Gain insights into relevant funding schemes? If you answer YES to any of the above, now is the time to register for the AIMday in Women's Health.

Link between COVID-19 infection and subsequent mental health and neurological conditions found

Coronavirus COVID-19 General Research

One in three COVID-19 survivors received a neurological or psychiatric diagnosis within six months of infection with the SARS-CoV-2 virus, an observational study of more than 230,000 patient health records published in The Lancet Psychiatry journal estimates. The study looked at 14 neurological and mental health disorders.

New national study of long-term impacts of debilitating lung damage from COVID-19

Coronavirus COVID-19 General Research

A new national study will investigate the long-term effects of lung inflammation and scarring from COVID-19. The study, launched with £2 million of funding from UK Research and Innovation (UKRI), aims to develop treatment strategies and prevent disability.

Opportunities for final goodbyes must be prioritised in COVID-19 pandemic

Coronavirus COVID-19 General Research

Bereaved relatives described the ongoing pain of being absent at the end of a loved-one's life. Many had not seen their relative for weeks or months due to the pandemic. Opportunities must be prioritised for essential connections between families at end-of-life care.